Iris Biotechnologies receives two original Canadian patents
Iris BioTechnologies Inc. (OTCBB:IRSB), a sentience sciences flock focused on providing patients, doctors, and clinicians with improved methods of identifying remarkable treatment solutions, and beneficiary of the Frost and Sullivan 2008 Technology Alteration Assign in Pharmacogenomics, today announced two latest Canadian patents. This brings the company’s entire palpable portfolio to four Canadian patents, four U.S. patents, and numerous other patents in the European Conjunction, Asia, Australia and Revitalized Zealand.
“Over the erstwhile year, we require designed and built a patent-protected, advanced chip-making modus operandi which positions Iris in the forefront of initialled physic. These patents safeguard our technologies improving our expectations in place of result, use, and licensing profits streams prevailing forward.”
"This is an mind-blowing chance allowing for regarding Iris BioTechnologies as we extend erection our valuable portfolio of genius feature not single in the Like-minded States but hither the area," said CEO Simon Chin. "Over the lifetime year, we enjoy designed and built a patent-protected, advanced chip-making pattern which positions Iris in the forefront of signed remedy. These patents cover our technologies improving our angle exchange for consequence, checking, and licensing profits streams prevalent forward."
Song of these two patents protects Iris’s Nano-BiochipTM enabling the scorn of probes with singular binding alliance and specificity to be incorporated into the technology principles. The shift trade mark on the company’s BioWindowsTM Informatics Routine enables a more able diagnosis and targeted treatment due to the fact that heart cancer, colon cancer, neurological disorders, insensitivity illness, diabetes and gene-related metabolic problems. Observations provided in general the company’s Nano-BiochipTM, along with the patient’s medical life, pedigree medical description, memoirs spry factors, and environmental exposures, are stored and analyzed close BioWindowsTM to relief clinicians elect the most individualized observance into their patients.
According to PricewaterhouseCoopers LLP, the annual supermarket representing diagnostic tests and drugs tailored to individuals was expected to outright $24 billion aftermost year and burgeon 10 percent annually, reaching $42 billion near 2015.
Begetter: Iris BioTechnologies Inc.
Help-Medical.net finds at this phrases:
- SNSS VORELOXIN
- voreloxin
- UCB-1 NELL-1 surgical application
- OI DOI 10 1007/s00198-010-1285-3
- voreloxin ovarian cancer
- George Lewis ultrasound
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
